Table 1 The correlations between BRMS1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma
Characteristic | Training set (n=120) | Testing set (n=154) | Overall patients (n=274) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | low | high | P * | low | high | P * | low | high | P * |
| Â | expression | expression | Â | expression | expression | Â | expression | expression | Â |
| Â | no. (%) | no. (%) | Â | no. (%) | no. (%) | Â | no. (%) | no. (%) | Â |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Male | 28 (66.7) | 60 (76.9) | 0.226 | 44 (77.2) | 74 (76.3) | 0.898 | 72 (72.7) | 134 (76.6) | 0.286 |
  Female | 14 (33.3) | 18 (23.1) |  | 13 (22.8) | 23 (23.7) |  | 27 (27.3) | 41 (23.4) |  |
Age (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  ≤ 46 | 20 (47.6) | 37 (47.4) | 0.985 | 31 (54.4) | 49 (50.5) | 0.643 | 51 (51.5) | 86 (49.1) | 0.401 |
  > 46 | 22 (52.4) | 41 (52.6) |  | 26 (45.6) | 48 (49.5) |  | 48 (49.5) | 89 (50.9) |  |
WHO type | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Type III | 40 (95.2) | 74 (94.9) | 1.000 | 56 (98.2) | 94 (96.9) | 1.000 | 96 (97.0) | 168 (96.0) | 0.482 |
  Other type | 2 (4.8) | 4 (5.1) |  | 1 (1.8) | 3 (3.1) |  | 3 (3.0) | 7 (4.0) |  |
VCA-IgA | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  ≥ 1:320 | 23(54.8) | 41(52.6) | 0.818 | 28(49.1) | 48(49.5) | 0.965 | 51(51.5) | 89(50.9) | 0.917 |
  < 1:320 | 19(45.2) | 37(47.4) |  | 29(50.9) | 49(50.5) |  | 48(48.5) | 86(49.1) |  |
EA-IgA | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  ≥ 1:20 | 20(47.6) | 43(55.1) | 0.432 | 33(57.9) | 50(51.5) | 0.445 | 53(53.5) | 93(53.1) | 0.950 |
  < 1:20 | 22(52.4) | 35(44.9) |  | 24(42.1) | 47(48.5) |  | 46(46.7) | 82(46.9) |  |
AER | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  ≥ 63% | 8(19.0) | 23(29.5) | 0.213 | 17(29.8) | 26(26.8) | 0.687 | 25(25.3) | 49(28.0) | 0.623 |
  < 63% | 34(81.0) | 55(70.5) |  | 40(70.2) | 71(73.2) |  | 74(74.7) | 126(72.0) |  |
UICC 7th T stage | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  T1 | 5 (11.9) | 16 (20.5) | 0.470 | 11 (19.3) | 18 (18.6) | 0.996 | 16 (16.2) | 34 (19.4) | 0.853 |
  T2 | 17 (40.5) | 22 (28.2) |  | 18 (31.6) | 32 (33.0) |  | 35 (35.4) | 54 (30.9) |  |
  T3 | 9 (21.4) | 19 (24.4) |  | 16 (28.1) | 26 (26.8) |  | 25 (25.3) | 45 (25.5) |  |
  T4 | 11 (26.2) | 21 (26.9) |  | 12 (21.1) | 21 (21.6) |  | 23 (23.2) | 42 (23.7) |  |
UICC 7th N stage | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  N0 | 4 (9.5) | 14 (17.9) | 0.644 | 8 (14.0) | 14 (14.4) | 0.837 | 12 (12.1) | 28 (16.0) | 0.732 |
  N1 | 22 (52.4) | 36 (46.2) |  | 24 (42.1) | 47 (48.5) |  | 46 (46.5) | 83 (47.4) |  |
  N2 | 10 (23.8) | 16 (20.5) |  | 15 (26.3) | 20 (20.6) |  | 25 (25.3) | 36 (20.6) |  |
  N3 | 6 (14.3) | 12 (15.4) |  | 10 (17.5) | 16 (16.5) |  | 16 (16.2) | 28 (16.0) |  |
Lymph node metastasis | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  No | 4 (9.5) | 14 (17.9) | 0.307 | 8 (14.0) | 14 (14.4) | 0.806 | 12 (12.1) | 28 (16.0) | 0.382 |
  Yes | 38 (90.5) | 64 (82.1) |  | 49 (86.0) | 83 (85.6) |  | 87 (87.9) | 147 (84.0) |  |
UICC 7th N stage | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  I | 0 (0.0) | 4 (5.1) | 0.513 | 1 (1.8) | 3 (3.1) | 0.949 | 8 (2.9) | 8 (2.9) | 0.538 |
  II | 13 (31.0) | 22 (28.2) |  | 17 (29.8) | 27 (27.8) |  | 79 (28.8) | 79 (28.8) |  |
  III | 13 (31.0) | 22 (28.2) |  | 19 (33.3) | 31 (32.0) |  | 85 (31.0) | 85 (31.0) |  |
  IV | 16 (38.0) | 30 (38.5) |  | 20 (35.1) | 36 (37.1) |  | 102 (37.2) | 102 (37.2) |  |
Distant metastasis# | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  No | 24 (57.1) | 67 (85.9) | 0.000 | 35 (61.4) | 83 (85.6) | 0.000 | 59 (59.6) | 150 (85.7) | 0.000 |
  Yes | 18 (42.8) | 11 (14.1) |  | 22 (38.6) | 14 (14.4) |  | 40 (40.4) | 25 (14.3) |  |